Supplementary Figure 1 from CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC
Rathi N. Pillai(Emory University), Johann C. Brandes(Emory University), Dana Nickleach(Johns Hopkins University), Seth A. Brodie, James G. Herman(UPMC Hillman Cancer Center), Fadlo R. Khuri(American University of Beirut Medical Center), Malcom V. Brock(Johns Hopkins University), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Suresh S. Ramalingam(Emory University), Yuan Liu(Genemo (United States)), Ge Li(Johns Hopkins University), Shaojin You(Atlanta Research and Education Foundation), Maria J.A. Ribeiro(Johns Hopkins University), Vijay Varma, Dacian Bonta(University of Chicago), Gabriel Sica(Emory University)
Cited by 0
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Inactivation of the DNA-Repair Gene<i>MGMT</i>and the Clinical Response of Gliomas to Alkylating Agents
|New England Journal of Medicine|2000|2.2k
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma
|Proceedings of the National Academy of Sciences|1998|1.9k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k